Zacks Research Issues Positive Estimate for TSE:BHC Earnings

Bausch Health Companies Inc. (TSE:BHC) – Analysts at Zacks Research boosted their Q3 2026 earnings estimates for Bausch Health Companies in a research report issued to clients and investors on Tuesday, September 22nd. Zacks Research analyst Team now expects that the company will earn $1.46 per share for the quarter, up from their previous forecast of $1.44. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.63 EPS and FY2028 earnings at $4.28 EPS.

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Bausch Health Companies Stock Down 0.9%

Shares of BHC stock opened at C$7.97 on Friday. The stock’s 50 day simple moving average is C$8.34 and its 200 day simple moving average is C$7.65. The company has a debt-to-equity ratio of -1,173.29, a quick ratio of 0.58 and a current ratio of 1.44. Bausch Health Companies has a twelve month low of C$6.10 and a twelve month high of C$11.08. The company has a market capitalization of C$2.98 billion, a price-to-earnings ratio of -2.71, a PEG ratio of 0.21 and a beta of 0.71.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. The company had revenue of C$4.05 billion during the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%.

Key Headlines Impacting Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks increased its FY2026 EPS forecast to $5.95 from $5.88, above the current full-year consensus estimate of $5.55. This is the most notable revision and could support the stock by signaling stronger near-term earnings potential. Bausch Health Companies stock information
• Positive Sentiment: The firm also raised its FY2027 EPS forecast to $5.40 from $5.33, Q3 2026 EPS to $1.46 from $1.44, and Q4 2026 EPS to $1.63 from $1.61. These upward revisions provide additional support for the earnings outlook.
• Positive Sentiment: Estimates for Q1, Q2, Q3 and Q4 2027 were each increased by $0.01, while the Q2 2028 estimate rose to $1.21 from $1.19. The broad-based, though small, upgrades indicate slightly better expectations extending beyond the current year.
• Neutral Sentiment: The revisions are analyst-estimate changes rather than confirmed financial results. Investors may therefore look for validation in Bausch Health’s next earnings report, particularly given the company’s substantial debt burden and negative net margin.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.